Humacyte (NASDAQ:HUMA – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued ...

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research report report ...

TD Cowen analyst Joshua Jennings lowered the firm’s price target on Humacyte (HUMA) to $7.50 from $10 and keeps a Buy rating on the shares. The ...

Trestle Biotherapeutics, Inc. recently announced a research collaboration with Humacyte, Inc. Trestle Bio is a ...

Humacyte (HUMA) announced the publication of the Budget Impact Model for Symvess in the Journal of Medical Economics. The publication, titled ...

Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals ...

The most recent trading session ended with Humacyte, Inc. (HUMA) standing at $2.99, reflecting a -0.33% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a $397.59 million market cap biotech company specializing in implantable bioengineered human tissues, has announced the publication of a Budget Impact ...

After hours: March 12 at 7:32:14 PM EDT Loading Chart for HUMA ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.